"The third quarter of 2024 was transformative for BioAge as we achieved two major milestones: initiating our Phase 2 STRIDES trial evaluating azelaprag in combination with tirzepatide, and completing ...

BioAge Labs (BIOA) announced that it will present new preclinical data for its lead product candidate azelaprag, an orally available small ...

Not only are deals going off at higher valuations than the companies initially anticipated, but the prices have been popping after the stocks began trading in the public markets. Observers are hoping ...

Septerna's protracted initial public offering (IPO) on the Nasdaq has finally reached its conclusion, with the final amount ...

2024 Weight-loss drug developer BioAge raises $198 mln in U.S. IPO September 26, 2024 Obesity drug developer BioAge Labs aims up to $640 mln valuation in upsized US IPO September 25, 2024 Obesity ...

Drug developers have achieved resounding success in the fall U.S. IPO market, with all the $100-million plus offerings since September upsized. Robust debuts by drug developers Bicara Therapeutics , ...

BioAge Labs, Inc. (BIOA) has received a new Buy rating, initiated by Morgan Stanley analyst, Jeffrey Hung. Jeffrey Hung’s rating is based ...

Hyundai Motors India IPO highlights: The Hyundai Motor IPO was subscribed 2.37 times overall by the close of bidding on October 17, 2024 (Day 3). Hyundai Motor IPO India Subscription Status ...

Hyundai IPO allotment: Share allotment for Hyundai Motor India IPO is expected on October 18, with shares listing on BSE and NSE on October 22. Hyundai Motor India's initial public offering (IPO ...

The Initial Public Offering (IPO) of Hyundai Motor India Limited, the Indian arm of South Korean automaker Hyundai, got fully subscribed on the third day of the bidding on Thursday (October 17, ...